Table 3.
Preoperative obesity-related comorbidities, n (%)
|
|
n
|
1SO, n = 80
|
1FAO, n = 80
|
χ
2
|
P value
|
n
|
2SO, n = 58
|
2FAO, n = 58
|
χ
2
|
P value
|
|
| MS | Without | 89 | 43 (53.8) | 46 (57.5) | 0.228 | 0.633 | 67 | 34 (58.6) | 33 (56.9) | 0.035 | 0.851 |
| With | 71 | 37 (46.3) | 34 (42.5) | 49 | 24 (41.4) | 25 (43.1) | |||||
| HTN | Without | 105 | 54 (67.5) | 51 (63.8) | 0.249 | 0.618 | 75 | 33 (56.9) | 42 (72.4) | 3.056 | 0.080 |
| With | 55 | 26 (32.5) | 29 (36.3) | 41 | 25 (43.1) | 16 (27.6) | |||||
| T2DM | Without | 86 | 43 (53.8) | 43 (53.8) | > 0.999 | 59 | 31 (53.4) | 28 (48.3) | 0.310 | 0.577 | |
| With | 74 | 37 (46.3) | 37 (46.3) | 57 | 27 (46.6) | 30 (51.7) | |||||
| IGT | Without | 89 | 45 (56.3) | 44 (55.0) | 0.025 | 0.874 | 71 | 33 (56.9) | 38 (65.5) | 0.908 | 0.341 |
| With | 71 | 35 (43.8) | 36 (45.0) | 45 | 25 (43.1) | 20 (34.5) | |||||
| HLP | Without | 96 | 51 (63.8) | 45 (56.3) | 0.938 | 0.333 | 68 | 39 (67.2) | 29 (50.0) | 3.554 | 0.059 |
| With | 64 | 29 (36.3) | 35 (43.8) | 48 | 19 (32.8) | 29 (50.0) | |||||
| PCOS | Without | 87 | 41 (74.5) | 46 (80.7) | 0.612 | 0.434 | 52 | 27 (77.1) | 25 (73.5) | 0.157 | 0.924 |
| With | 25 | 14 (25.5) | 11 (19.3) | 17 | 8 (22.9) | 9 (26.5) | |||||
| NAFLD | Without | 26 | 16 (20.0) | 10 (12.5) | 1.653 | 0.199 | 19 | 8 (13.8) | 11 (19.0) | 0.566 | 0.452 |
| With | 134 | 64 (80.0) | 70 (87.5) | 97 | 50 (86.2) | 47 (81.0) | |||||
| OSA | Without | 53 | 27 (33.8) | 26 (32.5) | 0.028 | 0.867 | 37 | 14 (24.1) | 23 (39.7) | 3.215 | 0.073 |
| With | 107 | 53 (66.3) | 54 (67.5) | 79 | 44 (75.9) | 35 (60.3) | |||||
| HUA | Without | 68 | 37 (46.3) | 31 (38.8) | 0.921 | 0.337 | 42 | 18 (31.0) | 24 (41.4) | 1.344 | 0.246 |
| With | 92 | 43 (53.8) | 49 (61.3) | 74 | 40 (69.0) | 34 (58.6) | |||||
Only female participants were analyzed to compare polycystic ovarian syndrome prevalence. The number of females is 112 [1sporadic obesity (SO) vs 1familial aggregation of obesity (FAO) = 55 vs 57] and 69 (2SO vs 2FAO = 35 vs 34). SO: Sporadic obesity; FAO: Familial aggregation of obesity; MS: Metabolic syndrome; HTN: Hypertension; T2DM: Type 2 diabetes mellitus; IGT: Impaired glucose tolerance; HLP: Hyperlipoidemia; PCOS: Polycystic ovarian syndrome; NAFLD: Non-alcoholic fatty liver disease; OSA: Obstructive sleep apnea; HUA: Hyperuricemia.